---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Administration. Questions: What is the recommended DATROWAY dose? What is the maximum dose of DATROWAY? What are the DATROWAY dose reduction levels? What DATROWAY premedications and supportive medications (eye drops, mouthwash) are recommended? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Dosing and administration questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Dosing

<a id="datroway-recommended-dose"></a>

### What is the recommended DATROWAY dose?

> “The recommended dosage of DATROWAY is 6 mg/kg (up to a maximum of 540 mg for patients ≥90 kg) administered as 
> an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.”

Source: [DATROWAY: Prescribing information, page 3, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=3)

<a id="datroway-maximum-dose"></a>

### What is the maximum dose of DATROWAY?

> “The recommended dosage of DATROWAY is 6 mg/kg (up to a maximum of 540 mg for patients ≥90 kg)”

Source: [DATROWAY: Prescribing information, page 3, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=3)

<a id="datroway-dose-reductions"></a>

### What are the DATROWAY dose reduction levels?

> “Table 2: Recommended Dosage Reductions of DATROWAY for Adverse Reactions 
> Dose Reductions 
> Recommended Dose 
>      First 
> 4 mg/kg (up to a maximum of 360 mg for patients ≥90 kg) 
>      Second 
> 3 mg/kg (up to a maximum of 270 mg for patients ≥90 kg) 
>      Third 
>     Permanently discontinue 
> Do not re-escalate the DATROWAY dose after a dose reduction. Permanently discontinue DATROWAY in patients who 
> are unable to tolerate 3 mg/kg intravenously once every 3 weeks.”

Source: [DATROWAY: Prescribing information, page 4, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=4)

<a id="datroway-premedication"></a>

### What DATROWAY premedications and supportive medications (eye drops, mouthwash) are recommended?

> “Premedication is recommended to help reduce the risk and severity of infusion-related reactions, nausea, and vomiting<sup>1</sup>”

Source: [DATROWAY: Dosing & Administration, captured 2026-11-08](https://datrowayhcp.com/dosing-administration#:~:text=Premedication%20is%20recommended%20to%20help,of%20infusion%2Drelated%20reactions%2C%20nausea%2C%20and)

> “Table 1: Premedication and Concomitant Medications”

Source: [DATROWAY: Prescribing information, page 3, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=3)

> “Eye drops 
> [see Warnings and Precautions (5.2)] 
> Preservative-free lubricant 
> eye drops 
> Administer at least four 
> times daily and as needed 
> Mouthwash 
> [see Warnings and Precautions (5.3)] 
> Steroid-containing 
> mouthwash (dexamethasone 
> oral solution 0.1 mg/mL) 
> Administer four times daily 
> and as needed 
> Antihistamine 
> [see Adverse Reactions (6.1)] 
> Diphenhydramine (25 to 
> 50 mg) administered 
> intravenously or orally 
> Administer 30-60 minutes 
> prior to each infusion 
> Antipyretic 
> [see Adverse Reactions (6.1)] 
> Acetaminophen (650 to 
> 1,000 mg) administered 
> intravenously or orally 
> Administer 30-60 minutes 
> prior to each infusion 
> Antiemetics 
> [see Adverse Reactions (6.1)] 
> 5-HT3 serotonin receptor 
> antagonist or appropriate 
> alternatives intravenously or 
> oral 
> Prior to each infusion and 
> thereafter as needed 
> <sup>a</sup> With or without systemic corticosteroid”

Source: [DATROWAY: Prescribing information, page 4, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=4)

<a id="datroway-missed-dose"></a>

### What if a DATROWAY dose is missed or delayed?

> “If a planned dose is missed or delayed, administer as soon as possible without waiting for the next cycle
> Adjust the schedule of administration to maintain a 3-week interval between doses”

Source: [DATROWAY: Dosing & Administration, captured 2026-11-08](https://datrowayhcp.com/dosing-administration#:~:text=If%20a%20planned%20dose%20is,a%203%2Dweek%20interval%20between%20doses)

## Administration

<a id="datroway-infusion-duration"></a>

### How long does a DATROWAY infusion take?

> “First infusion: Administer infusion over 90 minutes. Observe patients during the infusion and for at least 1 hour 
> following the initial dose for signs or symptoms of infusion-related reactions.  
> • 
> Second Infusion: If first infusion was tolerated, administer second infusion over 30 minutes. Observe patients 
> during the infusion and for at least 1 hour after infusion. 
> • 
> Subsequent Infusions: Administer infusion over 30 minutes if prior infusions were tolerated. Observe patients 
> during the infusion and for at least 30 min after infusion.”

Source: [DATROWAY: Prescribing information, page 6, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=6)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
